Benzinga | Aug 7, 2020 06:15AM EDT

Mersana Therapeutics Q2 EPS $(0.33) Misses $(0.30) Estimate, Sales $796.00K Beat $300.00K Estimate

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.30) by 10 percent. This is a 8.33 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $796.00 thousand which beat the analyst consensus estimate of $300.00 thousand by 165.33 percent. This is a 294.06 percent increase over sales of $202.00 thousand the same period last year.